(0.14%) 5 107.10 points
(0.22%) 38 324 points
(0.18%) 15 957 points
(-1.44%) $82.64
(5.77%) $2.03
(0.14%) $2 350.50
(-0.15%) $27.50
(3.87%) $957.75
(-0.21%) $0.933
(-0.35%) $10.99
(-0.53%) $0.796
(1.69%) $93.43
3.92% $ 9.27
@ $9.81
Ausgestellt: 14 Feb 2024 @ 20:26
Rendite: -5.46%
Vorheriges Signal: Feb 14 - 15:30
Vorheriges Signal:
Rendite: 1.82 %
Live Chart Being Loaded With Signals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B...
Stats | |
---|---|
Tagesvolumen | 104 622 |
Durchschnittsvolumen | 407 914 |
Marktkapitalisierung | 915.64M |
EPS | $-0.400 ( 2023-11-13 ) |
Nächstes Ertragsdatum | ( $-0.410 ) 2024-05-10 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -5.90 |
ATR14 | $0.0190 (0.20%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-03-31 | Chao David M | Sell | 10 385 | Ordinary Shares |
2024-03-31 | Weinhoff Gregory M | Sell | 11 742 | Ordinary Shares |
2024-03-31 | Saha Saurabh | Sell | 36 263 | Ordinary Shares |
2024-03-31 | Hussain Iqbal J | Sell | 7 520 | Ordinary Shares |
2024-03-31 | Bush Tia L | Sell | 6 419 | Ordinary Shares |
INSIDER POWER |
---|
61.95 |
Last 100 transactions |
Buy: 3 998 584 | Sell: 832 725 |
Volumen Korrelation
Centessa Pharmaceuticals Korrelation
10 Am meisten positiv korreliert | |
---|---|
UFPT | 0.914 |
TGAA | 0.912 |
RAMMU | 0.91 |
AMTBB | 0.907 |
PPSI | 0.904 |
TRON | 0.902 |
RDNT | 0.901 |
SKYW | 0.9 |
DFH | 0.899 |
NCAC | 0.898 |
10 Am meisten negativ korreliert | |
---|---|
HYRE | -0.907 |
VIVE | -0.903 |
TLGT | -0.89 |
QTEK | -0.881 |
BVXV | -0.879 |
BHTG | -0.876 |
ONEM | -0.874 |
TRMT | -0.873 |
JG | -0.862 |
SVVC | -0.859 |
Wussten Sie das?
Korrelation ist ein statistisches Maß, das die Beziehung zwischen zwei Variablen beschreibt. Es reicht von -1 bis 1, wobei -1 eine perfekte negative Korrelation (wenn eine Variable zunimmt, nimmt die andere ab) anzeigt, 1 eine perfekte positive Korrelation (wenn eine Variable zunimmt, nimmt die andere zu) und 0 keine Korrelation anzeigt (es besteht kein Zusammenhang zwischen den Variablen).
Korrelation kann verwendet werden, um die Beziehung zwischen beliebigen zwei Variablen zu analysieren, nicht nur zwischen Aktien. Es wird häufig in Bereichen wie Finanzen, Wirtschaft, Psychologie und mehr verwendet.
Centessa Pharmaceuticals Korrelation - Währung/Rohstoff
Centessa Pharmaceuticals Finanzdaten
Annual | 2023 |
Umsatz: | $6.88M |
Bruttogewinn: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2023 |
Umsatz: | $6.88M |
Bruttogewinn: | $6.07M (88.18 %) |
EPS: | $-1.580 |
FY | 2022 |
Umsatz: | $0 |
Bruttogewinn: | $-130 919 (0.00 %) |
EPS: | $-2.31 |
FY | 2021 |
Umsatz: | $0.00 |
Bruttogewinn: | $0.00 (0.00 %) |
EPS: | $-4.05 |
Financial Reports:
No articles found.
Centessa Pharmaceuticals
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Über Live-Signale
Die Live-Signale auf dieser Seite helfen dabei zu bestimmen, wann man NA kaufen oder verkaufen soll. Die Signale haben eine Verzögerung von bis zu 1 Minute; wie bei allen Marktsignalen besteht die Möglichkeit von Fehlern oder Fehleinschätzungen.
Die Live-Handelssignale sind nicht endgültig und getagraph.com übernimmt keine Verantwortung für Maßnahmen, die aufgrund dieser Signale ergriffen werden, wie in den Nutzungsbedingungen beschrieben. Die Signale basieren auf einer breiten Palette von technischen Analyseindikatoren.